Quantcast
ZME Science
  • News
  • Environment
  • Health
  • Future
  • Space
  • Features
    Menu
    Natural Sciences
    Health
    History & Humanities
    Space & Astronomy
    Technology
    Culture
    Resources
    Natural Sciences

    Physics

    • Matter and Energy
    • Quantum Mechanics
    • Thermodynamics

    Chemistry

    • Periodic Table
    • Applied Chemistry
    • Materials
    • Physical Chemistry

    Biology

    • Anatomy
    • Biochemistry
    • Ecology
    • Genetics
    • Microbiology
    • Plants and Fungi

    Geology and Paleontology

    • Planet Earth
    • Earth Dynamics
    • Rocks and Minerals
    • Volcanoes
    • Dinosaurs
    • Fossils

    Animals

    • Mammals
    • Birds
    • Fish
    • Reptiles
    • Amphibians
    • Invertebrates
    • Pets
    • Conservation
    • Animals Facts

    Climate and Weather

    • Climate Change
    • Weather and Atmosphere

    Geography

    Mathematics

    Health
    • Drugs
    • Diseases and Conditions
    • Human Body
    • Mind and Brain
    • Food and Nutrition
    • Wellness
    History & Humanities
    • Anthropology
    • Archaeology
    • Economics
    • History
    • People
    • Sociology
    Space & Astronomy
    • The Solar System
    • The Sun
    • The Moon
    • Planets
    • Asteroids, Meteors and Comets
    • Astronomy
    • Astrophysics
    • Cosmology
    • Exoplanets and Alien Life
    • Spaceflight and Exploration
    Technology
    • Computer Science & IT
    • Engineering
    • Inventions
    • Sustainability
    • Renewable Energy
    • Green Living
    Culture
    • Culture and Society
    • Bizarre Stories
    • Lifestyle
    • Art and Music
    • Gaming
    • Books
    • Movies and Shows
    Resources
    • How To
    • Science Careers
    • Metascience
    • Fringe Science
    • Science Experiments
    • School and Study
    • Natural Sciences
    • Health
    • History and Humanities
    • Space & Astronomy
    • Culture
    • Technology
    • Resources
  • Reviews
  • More
    • Agriculture
    • Anthropology
    • Biology
    • Chemistry
    • Electronics
    • Geology
    • History
    • Mathematics
    • Nanotechnology
    • Economics
    • Paleontology
    • Physics
    • Psychology
    • Robotics
  • About Us
    • About
    • The Team
    • Advertise
    • Contribute
    • Privacy Policy
    • Contact
No Result
View All Result
ZME Science

No Result
View All Result
ZME Science

Home → Science

First remdesivir results aren’t too promising, but things are far from clear

Antiviral drug touted as potential COVID-19 treatment is not doing too well, according to inadvertently released results.

Mihai Andrei by Mihai Andrei
April 30, 2020
in Health, News, Science

The good news is that results from the first official findings from the randomized trial of the antiviral drug remdesivir could come out earlier than anticipated, in the first weeks of May. The bad news is that the results might not be all we hoped for.

Remdesivir was first trialed against Ebola a few years ago, but it didn’t seem to go as well as was hoped for. The antiviral treatment recently gained a lot of attention as a potential treatment for COVID-19, with some promising preliminary results.

For instance, doctors at Houston Methodist Hospital told Reuters that since March 23, they have treated 41 mostly severely ill COVID-19 patients with the drug. None have died and half are back home. But this was not done in a clinical setting and therefore it’s impossible to know how much of this positive effect was owed to the drug itself, and how much was accounted for by other factors.

Several other hospitals shared similar data, and in early April 2020, remdesivir was viewed as the most promising potential treatment for COVID-19 by Johns Hopkins University. But things don’t look so good now.

The first negative data came with a draft published “by mistake” on the World Health Organization website summary. This was picked up by the media, who saved a screenshot of the study. The presented summary said the Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group. Remdesivir was stopped early in 18 patients because of side effects. After a month, 13.9 percent of the patients on remdesivir had died compared to 12.8 percent of those in the control group — a difference too small to be considered statistically significant.

However, Gilead (the company manufacturing remdesivir) said that negative characterization of the media is unwarranted.

“We believe the post included inappropriate characterizations of the study,” saying it was terminated early due to low enrollment and was therefore not statistically meaningful.

“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman added.

For now, it’s pretty unclear just how much potential remdesivir has, but there are already several large-scale trials ongoing, and a few are already in advanced stages. This means that in the not-too-distant-future, we could get a much clearer picture.

For instance, a very rigorous study supported by the NIH is set for publication in May. This is a randomized, double-blind, placebo-controlled trial, which means that the study compares patients who received remdesivir to those who didn’t, and neither the doctors nor the patients know who is getting the real drug and who is getting a placebo (to avoid all possible biases).

The study, which features patients from all around the world, progressed faster than expected and enrolled more patients than initially planned.

Dr. Andre Kalil, principal investigator for the trial, said he wants to see results that show “meaningful clinical benefits” for patients.

Was this helpful?
Thanks for your feedback!
Related posts:
  1. French scientists develop new class of promising antibiotics (so far, only in mice)
  2. Promising Zn-Mn battery can store a lot of energy, far cheaper than Lithium-ion
  3. WHO launches mega-trial of four of the most promising drugs against COVID-19
  4. Fingertip-sized skin patch delivers promising coronavirus vaccine
  5. The most promising coronavirus vaccine passes key safety trial
Tags: coronavirus

ADVERTISEMENT
  • News
  • Environment
  • Health
  • Future
  • Space
  • Features
  • Reviews
  • More
  • About Us

© 2007-2021 ZME Science - Not exactly rocket science. All Rights Reserved.

No Result
View All Result
  • News
  • Environment
  • Health
  • Future
  • Space
  • Features
    • Natural Sciences
    • Health
    • History and Humanities
    • Space & Astronomy
    • Culture
    • Technology
    • Resources
  • Reviews
  • More
    • Agriculture
    • Anthropology
    • Biology
    • Chemistry
    • Electronics
    • Geology
    • History
    • Mathematics
    • Nanotechnology
    • Economics
    • Paleontology
    • Physics
    • Psychology
    • Robotics
  • About Us
    • About
    • The Team
    • Advertise
    • Contribute
    • Privacy Policy
    • Contact

© 2007-2021 ZME Science - Not exactly rocket science. All Rights Reserved.

Don’t you want to get smarter every day?

YES, sign me up!

Over 35,000 subscribers can’t be wrong. Don’t worry, we never spam. By signing up you agree to our privacy policy.

✕
ZME Science News

FREE
VIEW